These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 9024269)

  • 1. The impact of insulin secretion on the ovarian response to exogenous gonadotropins in polycystic ovary syndrome.
    Fulghesu AM; Villa P; Pavone V; Guido M; Apa R; Caruso A; Lanzone A; Rossodivita A; Mancuso S
    J Clin Endocrinol Metab; 1997 Feb; 82(2):644-8. PubMed ID: 9024269
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polycystic ovary syndrome: relationship between insulin sensitivity, sex hormone levels and ovarian stromal blood flow.
    Loverro G; Vicino M; Lorusso F; Vimercati A; Greco P; Selvaggi L
    Gynecol Endocrinol; 2001 Apr; 15(2):142-9. PubMed ID: 11379011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evidence of a distinct derangement of opioid tone in hyperinsulinemic patients with polycystic ovarian syndrome: relationship with insulin and luteinizing hormone secretion.
    Lanzone A; Fulghesu AM; Cucinelli F; Ciampelli M; Caruso A; Mancuso S
    J Clin Endocrinol Metab; 1995 Dec; 80(12):3501-6. PubMed ID: 8530590
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The metabolic status modulates the effect of metformin on the antimullerian hormone-androgens-insulin interplay in obese women with polycystic ovary syndrome.
    Romualdi D; De Cicco S; Tagliaferri V; Proto C; Lanzone A; Guido M
    J Clin Endocrinol Metab; 2011 May; 96(5):E821-4. PubMed ID: 21307134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cabergoline influences ovarian stimulation in hyperprolactinaemic patients with polycystic ovary syndrome.
    Papaleo E; Doldi N; De Santis L; Marelli G; Marsiglio E; Rofena S; Ferrari A
    Hum Reprod; 2001 Nov; 16(11):2263-6. PubMed ID: 11679501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased insulin secretion in patients with multifollicular and polycystic ovaries and its impact on ovulation induction.
    Filicori M; Flamigni C; Cognigni G; Dellai P; Michelacci L; Arnone R
    Fertil Steril; 1994 Aug; 62(2):279-85. PubMed ID: 8034073
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Involvement of ovarian steroids in the opioid-mediated reduction of insulin secretion in hyperinsulinemic patients with polycystic ovary syndrome.
    Guido M; Pavone V; Ciampelli M; Murgia F; Fulghesu AM; Apa R; Caruso A; Mancuso S; Lanzone A
    J Clin Endocrinol Metab; 1998 May; 83(5):1742-5. PubMed ID: 9589685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does plasma insulin level affect ovarian response to exogenous administration of follicle-stimulating hormone in women without polycystic ovary syndrome?
    La Marca A; Pati M; Giulini S; Levratti P; Caretto S; Volpe A
    Gynecol Endocrinol; 2005 Nov; 21(5):292-4. PubMed ID: 16373249
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interactions between androgens, FSH, anti-Müllerian hormone and estradiol during folliculogenesis in the human normal and polycystic ovary.
    Dewailly D; Robin G; Peigne M; Decanter C; Pigny P; Catteau-Jonard S
    Hum Reprod Update; 2016 Nov; 22(6):709-724. PubMed ID: 27566840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metformin administration is more effective when non-obese patients with polycystic ovary syndrome show both hyperandrogenism and hyperinsulinemia.
    Genazzani AD; Lanzoni C; Ricchieri F; Baraldi E; Casarosa E; Jasonni VM
    Gynecol Endocrinol; 2007 Mar; 23(3):146-52. PubMed ID: 17454168
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Androstenedione response to recombinant human FSH is the most valid predictor of the number of selected follicles in polycystic ovarian syndrome: (a case-control study).
    Ozyurek ES; Yoldemir T; Artar G
    J Ovarian Res; 2017 May; 10(1):34. PubMed ID: 28494798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Specific factors predict the response to pulsatile gonadotropin-releasing hormone therapy in polycystic ovarian syndrome.
    Gill S; Taylor AE; Martin KA; Welt CK; Adams JM; Hall JE
    J Clin Endocrinol Metab; 2001 Jun; 86(6):2428-36. PubMed ID: 11397835
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pituitary-ovarian response to the gonadotrophin-releasing hormone-agonist test in anovulatory patients with polycystic ovary syndrome: predictive role of ovarian stroma.
    Fulghesu AM; Angioni S; Belosi C; Apa R; Selvaggi L; Ciampelli M; Iuculano A; Melis GB; Lanzone A
    Clin Endocrinol (Oxf); 2006 Sep; 65(3):396-401. PubMed ID: 16918963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of urinary human follicle-stimulating hormone and human menopausal gonadotropin for ovarian stimulation in polycystic ovarian syndrome.
    Larsen T; Larsen JF; Schiøler V; Bostofte E; Felding C
    Fertil Steril; 1990 Mar; 53(3):426-31. PubMed ID: 2106449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gonadotropin-releasing hormone antagonist and metformin for treatment of polycystic ovary syndrome patients undergoing in vitro fertilization-embryo transfer.
    Doldi N; Persico P; Di Sebastiano F; Marsiglio E; Ferrari A
    Gynecol Endocrinol; 2006 May; 22(5):235-8. PubMed ID: 16785142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-dose follicle stimulating hormone for ovulation induction in polycystic ovary syndrome.
    Strowitzki T; Seehaus D; Korell M; Hepp H
    J Reprod Med; 1994 Jul; 39(7):499-503. PubMed ID: 7966037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does metformin affect the ovarian response to gonadotropins for in vitro fertilization treatment in patients with polycystic ovary syndrome and reduced ovarian reserve? A randomized controlled trial.
    Palomba S; Falbo A; Di Cello A; Cappiello F; Tolino A; Zullo F
    Fertil Steril; 2011 Nov; 96(5):1128-33. PubMed ID: 21917254
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized controlled trial evaluating metformin pre-treatment and co-administration in non-obese insulin-resistant women with polycystic ovary syndrome treated with controlled ovarian stimulation plus timed intercourse or intrauterine insemination.
    Palomba S; Falbo A; Orio F; Manguso F; Russo T; Tolino A; Annamaria C; Dale B; Zullo F
    Hum Reprod; 2005 Oct; 20(10):2879-86. PubMed ID: 15958399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of metformin on insulin secretion, insulin action, and ovarian steroidogenesis in women with polycystic ovary syndrome.
    Ehrmann DA; Cavaghan MK; Imperial J; Sturis J; Rosenfield RL; Polonsky KS
    J Clin Endocrinol Metab; 1997 Feb; 82(2):524-30. PubMed ID: 9024248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of a somatostatin analogue in lowering luteinizing hormone and insulin-stimulated secretion in hyperinsulinemic women with polycystic ovary disease.
    Fulghesu AM; Lanzone A; Andreani CL; Pierro E; Caruso A; Mancuso S
    Fertil Steril; 1995 Oct; 64(4):703-8. PubMed ID: 7672138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.